
Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions
Ginecologia e ObstetríciaResumo original em inglês
O que aconteceu
Cervical cancer screening programs, including triage tests, need redesigning as human papillomavirus (HPV)-vaccinated women are entering the programs. Methylation markers offer a potential solution to reduce false-positive rates by identifying clinically relevant cervical lesions with progressive potential. In a nested case-control study, 9242 women who received the three-dose HPV16/18-vaccine at ages 12-15 or 18 in a community-randomized trial were included. Subsequently, they were re-randomized for either frequent or infrequent cervical cancer screening trials. Over a 15-year post-vaccination follow-up until 2022, 17 high-grade squamous intraepithelial lesion (HSIL) and 15 low-grade (LSIL) cases were identified at the 25-year screening round, alongside 371 age and community-matched HPV16/18-vaccinated controls. Methylation analyses were performed on cervical samples collected at age 25, preceding histologically confirmed LSIL or HSIL diagnoses. DNA methylation of viral (HPV16/18/31/33) and host-cell genes (EPB41L3, FAM19A4, and miR124-2) was measured, along with HPV-genotyping. No HPV16/18 HSIL cases were observed. The predominant HPV-genotypes were HPV52 (29.4%), HPV59/HPV51/HPV58 (each 23.5%), and HPV33 (17.7%). Methylation levels were generally low, with no significant differences in mean methylation levels of viral or host-cell genes between the LSIL/HSIL and controls. However, a significant difference in methylation levels was found between HSIL cases and controls when considering a combination of viral genes and EPB41L3 (p value = .0001). HPV-vaccinated women with HSIL had HPV infections with uncommon HPV types that very rarely cause cancer and displayed low methylation levels. Further investigation is warranted to understand the likely regressive nature of HSIL among HPV-vaccinated women and its implications for management.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions
Karolina Louvanto, Lisanne Verhoef, Ville N Pimenoff, Tiina Eriksson, Siiri Leppälä, Camilla Lagheden, Penelope Gray, Dorota Scibior-Bentkowska, Elizabeth Sumiec, Pekka Nieminen et al.
Descritores MeSH
- DNA Methylation
- Uterine Cervical Neoplasms
- Papillomavirus Vaccines
- Papillomavirus Infections
- Adolescent
- Child
- Uterine Cervical Dysplasia
- Humans
- Biomarkers, Tumor
- Female
Veja também
Estudos relacionados
- Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis
- Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women
- Meta-análise do desempenho da metilação PAX1/JAM3 em mulheres com HPV de alto risco
- Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis